

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma ID3742

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Merck Sharpe & Dohme (pembrolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Black Health Agency for Equality Cancer Black Care Cancer Equality Cancer Research UK Cancer 52 GIST Cancer UK GUTS UK Heartburn UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie’s Centres Marie Curie Ochre Oesophageal Patients Association PAWS GIST Clinic South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Together Support Group <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Scottish Society of Gastroenterology Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Accord Healthcare (capecitabine, cisplatin, epirubicin, fluorouracil, oxaliplatin, trastuzumab) Amgen (trastuzumab) Celltrion Healthcare (trastuzumab) Dr. Reddy’s Laboratories (capecitabine) Glenmark Pharmaceuticals (capecitabine) Hospira UK (cisplatin, fluorouracil, oxaliplatin)

Final stakeholder list for the evaluation of pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma ID3742

Issue date: March 2023

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • medac (epirubicin, fluorouracil, oxaliplatin) • Morningside Healthcare (capecitabine) • Organon Pharma (trastuzumab) • Pfizer (epirubicin, trastuzumab) • Ranbaxy (oxaliplatin) • Roche (trastuzumab) • Sandoz (cisplatin) • Seacross Pharmaceuticals (epirubicin, oxaliplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane UK • Cochrane Upper Gastrointestinal and Pancreatic Diseases Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research • Oracle Cancer Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.